{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:21:52Z","timestamp":1770747712868,"version":"3.49.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.7759\/cureus.80627","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T21:11:16Z","timestamp":1742073076000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Epistaxis Due to Risankizumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Judith P","family":"Vinod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Delange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Biglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"62","author":"Kristensen LE","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, et al.. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2023, 62:2113-21. 10.1093\/rheumatology\/keac607","journal-title":"Rheumatology (Oxford)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon KB","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al.. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022, 186:466-75. 10.1111\/bjd.20818","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071933","article-title":"Pharmacovigilance of risankizumab in the treatment of psoriasis and arthritic psoriasis: real-world data from EudraVigilance database","volume":"15","author":"Calapai F","year":"2023","unstructured":"Calapai F, Ammendolia I, Cardia L, Curr\u00f2 M, Calapai G, Esposito E, Mannucci C. Pharmacovigilance of risankizumab in the treatment of psoriasis and arthritic psoriasis: real-world data from EudraVigilance database. Pharmaceutics. 2023, 15:10.3390\/pharmaceutics15071933","journal-title":"Pharmaceutics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0194599819890327","article-title":"Clinical practice guideline: nosebleed (epistaxis)","volume":"162","author":"Tunkel DE","year":"2020","unstructured":"Tunkel DE, Anne S, Payne SC, et al.. Clinical practice guideline: nosebleed (epistaxis). Otolaryngol Head Neck Surg. 2020, 162:S1-S38. 10.1177\/0194599819890327","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref5","unstructured":"Skyrizi. (2024). Accessed. 12\/20\/2024: https:\/\/www.pdr.net\/drug-summary\/?drugLabelId=24336."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336661-severe-epistaxis-due-to-risankizumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T21:11:19Z","timestamp":1742073079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336661-severe-epistaxis-due-to-risankizumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.80627","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,15]]}}}